Completed PHASE1/PHASE2 INTERVENTIONAL NCT00140348

Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine

A Phase I/II Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine in Patients With Metastatic Hormone-Refractory Prostate Cancer

Sponsor: Cell Genesys

Conditions Prostate Cancer

Interventions Immunotherapy allogeneic GM-CSF secreting cellular vaccine

Updated 5 times since 2017 Last updated: Dec 18, 2007 Started: Dec 31, 2001 Completion: Apr 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00140348, this PHASE1/PHASE2 trial focuses on Prostate Cancer and remains completed. Sponsored by Cell Genesys, it has been updated 5 times since 2001, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Dec 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cell Genesys

Data source: Cell Genesys

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Atlanta, United States , Aventura, United States , Fort Wayne, United States , Laguna Woods, United States , Philadelphia, United States , San Antonio, United States , San Francisco, United States , Seattle, United States , Tarzana, United States and 1 more location